6425 related articles for article (PubMed ID: 11566020)
1. Genasense (Genta Inc).
Banerjee D
Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
[TBL] [Abstract][Full Text] [Related]
2. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
3. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
Frankel SR
Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
[TBL] [Abstract][Full Text] [Related]
4. Technology evaluation: G-3139.
Banerjee D
Curr Opin Mol Ther; 1999 Jun; 1(3):404-8. PubMed ID: 11713806
[TBL] [Abstract][Full Text] [Related]
5. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis, Bcl-2 antisense, and cancer therapy.
Piro LD
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
[TBL] [Abstract][Full Text] [Related]
7. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
[TBL] [Abstract][Full Text] [Related]
8. [Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results].
Büchele T
Onkologie; 2003 Dec; 26 Suppl 7():60-9. PubMed ID: 14716145
[TBL] [Abstract][Full Text] [Related]
9. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
10. Genta initiates trials with Genasense.
Expert Rev Anticancer Ther; 2002 Feb; 2(1):6. PubMed ID: 12113068
[No Abstract] [Full Text] [Related]
11. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
12. Thymitaq (Zarix).
Niculescu-Duvaz I
Curr Opin Investig Drugs; 2001 May; 2(5):693-705. PubMed ID: 11569949
[TBL] [Abstract][Full Text] [Related]
13. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
Klasa RJ; Gillum AM; Klem RE; Frankel SR
Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
[TBL] [Abstract][Full Text] [Related]
14. GTI-2040. Lorus Therapeutics.
Orr RM
Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
[TBL] [Abstract][Full Text] [Related]
15. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW
Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483
[TBL] [Abstract][Full Text] [Related]
16. Clofarabine.
Drugs R D; 2004; 5(4):213-7. PubMed ID: 15230627
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides.
Nichols GL; Stein CA
Semin Oncol; 2003 Apr; 30(2):297-9. PubMed ID: 12720156
[TBL] [Abstract][Full Text] [Related]
18. G 3139. Augmerosen, Bcl-2 antisense oligonucleotide--Genta, GC 3139, Genasense.
Drugs R D; 2002; 3(1):44-9. PubMed ID: 11881530
[No Abstract] [Full Text] [Related]
19. Bcl-2 antisense therapy in B-cell malignancies.
Chanan-Khan A
Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
[TBL] [Abstract][Full Text] [Related]
20. Oblimersen in the treatment of metastatic melanoma.
Tarhini AA; Kirkwood JM
Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]